Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pronostic factors of synchronous brain metastases from lung cancer
Autore:
Penel, N; Brichet, A; Prevost, B; Duhamel, A; Assaker, R; Dubois, FO; Lafitte, JJ;
Indirizzi:
Oscar Lambret Canc Ctr, F-59020 Lille, France Oscar Lambret Canc Ctr Lille France F-59020 c Ctr, F-59020 Lille, France Univ Lille, Calmette Hosp, Dept Pneumol, Lille, France Univ Lille Lille France lle, Calmette Hosp, Dept Pneumol, Lille, France Univ Lille, Huriez Hosp, Dept Biostat, Lille, France Univ Lille Lille France Lille, Huriez Hosp, Dept Biostat, Lille, France Univ Lille, Salengro Hosp, Dept Neurosurg, Lille, France Univ Lille Lille France e, Salengro Hosp, Dept Neurosurg, Lille, France
Titolo Testata:
LUNG CANCER
fascicolo: 2-3, volume: 33, anno: 2001,
pagine: 143 - 154
SICI:
0169-5002(200108/09)33:2-3<143:PFOSBM>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOLITARY CEREBRAL METASTASIS; PROGNOSTIC FACTORS; SURGICAL-TREATMENT; RADIATION-THERAPY; BRONCHOGENIC CARCINOMA; SYSTEMIC CHEMOTHERAPY; ADJUVANT RADIATION; CELL-CARCINOMA; SURVIVAL; RESECTION;
Keywords:
brain metastases; lung cancer; prognostic factor; neurosurgery; brain radiotherapy; chemotherapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
51
Recensione:
Indirizzi per estratti:
Indirizzo: Penel, N Oscar Lambret Canc Ctr, 3 Rue Frederic Combeinale,BP 307, F-59020Lille, France Oscar Lambret Canc Ctr 3 Rue Frederic Combeinale,BP 307 Lille France F-59020
Citazione:
N. Penel et al., "Pronostic factors of synchronous brain metastases from lung cancer", LUNG CANC, 33(2-3), 2001, pp. 143-154

Abstract

Background: The prognosis of brain metastases (BM) from lung cancer is poor. The management of lung cancer with BM is not clear. This retrospective study attempts to determine their prognostic factors, and to better define the role of different treatments, Methods: We reviewed the clinical characteristics of 271 consecutive patients with synchronous brain metastases (SBM)from lung cancer (small-cell lung cancers and non-small-cell lung cancers), collected between January 1985 and May 1993. Data were available for all patients as well as follow-up information on all patients through to death. Patients had all undergone heterogeneous treatments. Each physician had chosen the appropriate treatment after collegiate discussion. Survival curveswere compared using the log-rank test in univariate analysis, and Cox's Regression model in multivariate analysis. Statistical significance was defined as P < 0.05. Results: 249 patients were assessable. Treatments included:neurosurgical resection in 56 cases, brain irradiation in 87 cases, and chemotherapy in 126 cases. Median overall survival time from the date of histological diagnosis of SBM was 103 days (range, 1-1699). In multivariate analysis, prognostic factors for longer overall survival times were: absence of adrenal metastases (P = 0.007), neurosurgical resection (P = 0.028), chemotherapy (P = 0.032) and brain irradiation (P = 0.008). Moreover, risk factors of intracranial hypertension as cause of death were number of SBM and absence of neurosurgical resection. Conclusions: These results and others suggest that patients with SBM from lung cancer be considered for carcinologic treatment, and not only for best supportive care. However, further studies are necessary to evaluate quality of life with or without carcinologic treatment. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 11:06:24